Is Hims and Hers Health Stock a Buy After Its Latest Dip?

Hims & Hers raised full-year revenue guidance to $2.8 billion-$3.0 billion, but cut adjusted EBITDA outlook to $275 million-$350 million from $300 million-$375 million, signaling significant margin compression. Q1 revenue rose 4% to $608.1 million, but adjusted EBITDA fell 51% to $44.3 million and EPS swung to a $0.40 loss from a $0.20 profit. Management’s growth is being driven by branded weight-loss drugs, while potential upside from peptides remains speculative pending FDA action.

Analysis

The market is likely focusing on the wrong line item: the revenue beat is less important than the mix shift from high-IRR recurring prescription/refill economics into a lower-margin acquisition channel. That typically creates a one-to-two quarter lag before the full margin reset shows up in sell-side models, so the next downtick risk is not just to EBITDA but to valuation multiples as investors re-underwrite lifetime value per customer. In other words, this is less a demand story than a unit-economics story, and those usually compress harder than consensus expects once CAC rises and pricing power weakens.

The real second-order effect is competitive. If HIMS is using branded weight-loss exposure to buy growth, it implicitly subsidizes the customer acquisition efforts of every telehealth and compounding-adjacent competitor in the category. That can force a broader industry margin race, especially if larger players or pharma-affiliated distribution channels decide to defend share with promo intensity or bundle economics. The international acceleration is also a double-edged sword: it improves headline growth, but it often carries lower operating leverage early on and can obscure the underlying slowdown in the core U.S. engine.

The peptide angle is the only credible catalyst that can re-rate the stock, but the timeline is not immediate and the binary risk is high. A regulatory reversal would likely take months, not weeks, and the market will discount approval probability long before any formal change; until then, the stock is trading on optionality rather than fundamentals. That creates a classic setup where implied upside from the narrative may be larger than the near-term revenue contribution, but the downside from continued margin erosion is tangible and near-term.

Consensus may still be underestimating how quickly sentiment can flip from ‘growth at any cost’ to ‘quality of growth matters’ once EBITDA revisions compound. If margins stabilize, the stock can rebound sharply because positioning is likely crowded on the short side; but absent a policy catalyst, the better risk/reward is to wait for evidence that new cohorts monetize better, not just faster.

Key Decisions for Investors

• Reduce or avoid outright long exposure to HIMS for the next 1-2 quarters; the asymmetry is poor while EBITDA estimates are still sliding and multiple compression can continue even if revenue beats.
• For tactical traders, consider a put spread on HIMS into the next earnings cycle with 6-10 week tenor; target a move lower on any further margin guide reset, but keep defined risk because peptide headlines can gap the stock higher.
• If seeking event-driven upside, buy a small speculative call spread on HIMS only on a confirmed FDA-policy catalyst around peptides; treat it as a binary optionality trade, not a core long, and size accordingly.
• Pair trade idea: long NVO / short HIMS for 1-3 months if you want exposure to branded obesity demand without taking single-name execution risk; the trade benefits if HIMS continues to fund growth with weaker economics while the incumbent captures the more durable margin pool.
• Wait on any long HIMS entry until adjusted EBITDA stabilizes sequentially for at least one quarter; if that does not happen, the stock should be treated as a momentum/trading vehicle rather than a fundamental compounder.